Wadowski Benjamin, Bueno Raphael, De Rienzo Assunta
Thoracic Surgery Oncology Laboratory and the International Mesothelioma Program, Division of Thoracic and Cardiovascular Surgery, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, United States.
Front Oncol. 2021 Jun 11;11:684025. doi: 10.3389/fonc.2021.684025. eCollection 2021.
Malignant pleural mesothelioma (MPM) is a rare and aggressive malignancy with limited therapeutic options beyond surgery and cytotoxic chemotherapy. The success of immune checkpoint inhibition has been found to correlate with expression of immune-related genes such as (PD-L1) in lung and other solid cancers. However, only a small subset of MPM patients respond to checkpoint inhibition, and this response has been varied and unpredictable across several clinical trials. Recent advances in next-generation sequencing (NGS) technology have improved our understanding of the molecular features of MPM, also with respect to its genetic signature and how this impacts the immune microenvironment. This article will review current evidence surrounding the interplay between MPM genetics, including epigenetics and transcriptomics, and the immune response.
恶性胸膜间皮瘤（MPM）是一种罕见且侵袭性强的恶性肿瘤，除手术和细胞毒性化疗外，治疗选择有限。免疫检查点抑制的成功已被发现与肺及其他实体癌中免疫相关基因如（程序性死亡受体配体1，PD-L1）的表达相关。然而，只有一小部分MPM患者对检查点抑制有反应，并且在多项临床试验中，这种反应各不相同且不可预测。新一代测序（NGS）技术的最新进展增进了我们对MPM分子特征的理解，包括其基因特征以及这如何影响免疫微环境。本文将综述围绕MPM遗传学（包括表观遗传学和转录组学）与免疫反应之间相互作用的现有证据。
